Equities analysts forecast that Integra Lifesciences Holdings Corp (NASDAQ:IART) will announce earnings of $0.56 per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Integra Lifesciences’ earnings, with the lowest EPS estimate coming in at $0.54 and the highest estimate coming in at $0.61. Integra Lifesciences posted earnings of $0.52 per share during the same quarter last year, which indicates a positive year over year growth rate of 7.7%. The business is expected to announce its next quarterly earnings report on Thursday, February 22nd.
According to Zacks, analysts expect that Integra Lifesciences will report full year earnings of $1.85 per share for the current financial year, with EPS estimates ranging from $1.83 to $1.90. For the next year, analysts anticipate that the company will post earnings of $2.29 per share, with EPS estimates ranging from $2.26 to $2.31. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The firm had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. During the same period in the prior year, the business earned $0.93 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis.
A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 13th. Oppenheimer set a $58.00 target price on shares of Integra Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Jefferies Group reaffirmed a “buy” rating and issued a $58.00 target price on shares of Integra Lifesciences in a research note on Thursday, October 12th. UBS reaffirmed a “buy” rating and issued a $57.00 target price on shares of Integra Lifesciences in a research note on Tuesday, October 31st. Finally, J P Morgan Chase & Co downgraded shares of Integra Lifesciences from an “overweight” rating to a “neutral” rating and set a $44.00 target price for the company. in a research note on Friday, October 27th. One analyst has rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the stock. Integra Lifesciences has a consensus rating of “Hold” and an average price target of $53.64.
Shares of Integra Lifesciences (IART) traded down $0.21 during mid-day trading on Friday, reaching $49.76. 314,200 shares of the company traded hands, compared to its average volume of 594,666. Integra Lifesciences has a 12-month low of $40.51 and a 12-month high of $56.42. The company has a market cap of $3,921.52, a P/E ratio of 27.61, a P/E/G ratio of 2.10 and a beta of 0.65. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26.
In related news, VP Richard D. Gorelick sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the sale, the vice president now directly owns 21,665 shares of the company’s stock, valued at $1,022,371.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Barbara B. Hill acquired 10,768 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The shares were purchased at an average price of $46.66 per share, with a total value of $502,434.88. Following the acquisition, the director now owns 55,540 shares of the company’s stock, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. Insiders own 21.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of IART. Capital Research Global Investors grew its holdings in Integra Lifesciences by 227.0% during the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after purchasing an additional 2,705,488 shares during the period. Janus Henderson Group PLC acquired a new position in Integra Lifesciences during the second quarter valued at approximately $112,068,000. Koch Industries Inc. grew its holdings in Integra Lifesciences by 12,623.4% during the second quarter. Koch Industries Inc. now owns 754,880 shares of the life sciences company’s stock valued at $741,000 after purchasing an additional 748,947 shares during the period. Orbimed Advisors LLC grew its holdings in Integra Lifesciences by 155.5% during the third quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after purchasing an additional 664,000 shares during the period. Finally, FMR LLC grew its holdings in Integra Lifesciences by 6.2% during the second quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after purchasing an additional 468,678 shares during the period. Hedge funds and other institutional investors own 87.58% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “$0.56 Earnings Per Share Expected for Integra Lifesciences Holdings Corp (IART) This Quarter” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/12/0-56-earnings-per-share-expected-for-integra-lifesciences-holdings-corp-iart-this-quarter.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Get a free copy of the Zacks research report on Integra Lifesciences (IART)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.